Cystic fibrosis biotech Sionna Therapeutics will raise $191 million in its upsized Nasdaq debut on Friday, and metabolic ...

Almost 16 years after Rituxan's disappointing data in lupus, Roche's Genentech found success with a different B cell-killing ...

AstraZeneca has terminated all development of vemircopan, the oral factor D inhibitor it acquired through the deal for ...

Acelyrin merges with Alumis in all-stock deal, transferring $448M cash and lonigutamab asset. Martin Babler to lead combined ...

B Health and two hospitals seek to intervene in Eli Lilly lawsuit, saying proposed rebate model would burden hospitals with ...

It took one month for Johnson & Johnson to secure its $14 billion acquisition of Intra-Cellular Therapies, according to new ...

AstraZeneca cuts UK investment after government reduces site expansion support; Viking secures API supply; Jabil acquires ...

Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials ...

After promoting its oncology officer Chris Boshoff to chief scientific officer last fall, Pfizer has found his successor.

Per­son­i­fy Health, which sells health­care spend­ing man­age­ment ser­vices to em­ploy­ers, has reached more than half a ...

Progyny acquires BenefitBump and Teladoc buys Catapult Health for $65M, as digital health companies engage in dealmaking.

Bristol Myers Squibb announces $2B in new cost cuts over 3 years, including workforce reductions, following $1.5B cuts in ...